Literature DB >> 7511045

Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation.

J Kokontis1, K Takakura, N Hay, S Liao.   

Abstract

Proliferation of LNCaP 104-S cells, a clonal subline of the human prostate cancer cell line, was very slow in androgen-depleted medium but increased 10-13-fold in the presence of 0.1 nM of a synthetic androgen, R1881. This induction of proliferation was diminished at higher concentrations of R1881, indicating the biphasic nature of the androgen effect. After 20-30 passages in androgen-depleted medium, these cells progressed to 104-I cells, which exhibited much lower proliferative sensitivity to 0.1 nM R1881. After another 20-30 passages, LNCaP 104-I cells gave rise to 104-R cells, which proliferated rapidly without additional androgen. Proliferation of 104-R cells was induced 2-fold by 0.01 nM R1881 but was repressed by 0.1 nM R1881 and above. Thus, androgen induction and repression of proliferation could be seen at lower concentrations of androgen as the cells progressed. During the transition of 104-S cells to 104-R cells, the androgen receptor mRNA level increased 2.5-fold whereas the androgen receptor protein level increased 15-fold in the absence of androgen. Androgen receptor transcriptional activity, measured by androgen induction of prostate-specific antigen mRNA and chloramphenicol acetyltransferase activity in transfected cells, increased up to 20-fold during the progression. LNCaP cells, therefore, appear to be able to adapt to reduced androgen availability by increasing their sensitivity to androgen, raising questions concerning the therapeutic strategies used against prostate cancer. Androgen induction of c-myc expression in 104-R cells occurred at a 10-fold lower concentration (0.01 nM) than in 104-S cells (0.1 nM). In all stages, cell proliferation and c-myc expression were repressed by androgen at a high concentration (20 nM), but the repression of cell proliferation was blocked by retroviral overexpression of c-myc.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7511045

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  56 in total

Review 1.  Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents.

Authors:  R Montironi; R Mazzucchelli; J R Marshall; P H Bartels
Journal:  J Clin Pathol       Date:  1999-11       Impact factor: 3.411

2.  Androgen and its receptor promote Bax-mediated apoptosis.

Authors:  Yuting Lin; John Kokontis; Fangming Tang; Bradley Godfrey; Shutsung Liao; Anning Lin; Youting Chen; Jialing Xiang
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

3.  Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.

Authors:  Michael J Morris; Daisy Huang; William K Kelly; Susan F Slovin; Ryan D Stephenson; Caitlin Eicher; Anthony Delacruz; Tracy Curley; Lawrence H Schwartz; Howard I Scher
Journal:  Eur Urol       Date:  2009-04-03       Impact factor: 20.096

4.  Glutamine Transporters Are Targets of Multiple Oncogenic Signaling Pathways in Prostate Cancer.

Authors:  Mark A White; Chenchu Lin; Kimal Rajapakshe; Jianrong Dong; Yan Shi; Efrosini Tsouko; Ratna Mukhopadhyay; Diana Jasso; Wajahat Dawood; Cristian Coarfa; Daniel E Frigo
Journal:  Mol Cancer Res       Date:  2017-05-15       Impact factor: 5.852

5.  Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance.

Authors:  Gregor M Balaburski; Rita C Dardes; Michael Johnson; Bassem Haddad; Fang Zhu; Eric A Ross; Surojeet Sengupta; Andres Klein-Szanto; Hong Liu; Eun Sook Lee; Helen Kim; V Craig Jordan
Journal:  Int J Oncol       Date:  2010-08       Impact factor: 5.650

6.  Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride.

Authors:  Y Umekita; R A Hiipakka; J M Kokontis; S Liao
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

7.  Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform.

Authors:  Caitlin Lynch; Srilatha Sakamuru; Ruili Huang; Diana A Stavreva; Lyuba Varticovski; Gordon L Hager; Richard S Judson; Keith A Houck; Nicole C Kleinstreuer; Warren Casey; Richard S Paules; Anton Simeonov; Menghang Xia
Journal:  Toxicology       Date:  2017-05-04       Impact factor: 4.221

8.  HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling.

Authors:  Young-Rang Kim; Kyung-Jin Oh; Ra-Young Park; Nguyen Thi Xuan; Taek-Won Kang; Dong-Deuk Kwon; Chan Choi; Min Soo Kim; Kwang Il Nam; Kyu Youn Ahn; Chaeyong Jung
Journal:  Mol Cancer       Date:  2010-05-27       Impact factor: 27.401

9.  LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion.

Authors:  Yirong Li; Longgui Wang; Miao Zhang; Jonathan Melamed; Xiaomei Liu; Robert Reiter; Jianjun Wei; Yi Peng; Xuanyi Zou; Angel Pellicer; Michael J Garabedian; Anna Ferrari; Peng Lee
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

Review 10.  The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer.

Authors:  Sheng-Qiang Yu; Kuo-Pao Lai; Shu-Jie Xia; Hong-Chiang Chang; Chawnshang Chang; Shuyuan Yeh
Journal:  Asian J Androl       Date:  2008-12-22       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.